FDA and Merck warn against using Victrelis with some HIV drugs

The FDA warned that combining Merck & Co.'s hepatitis C medicine Victrelis with ritonavir-boosted HIV drugs can potentially reduce the effectiveness of both regimens. Merck said Victrelis lowered blood concentration of antivirals Prezista, Kaletra and Reyataz by 43% to 59% during a study. Drug-interaction data will be added to Victrelis' label, according to the FDA and Merck. The Wall Street Journal/Dow Jones Newswires

Source: AABBsmartbrief